Log In
Print this Print this

eribulin mesylate (E7389-LF)

  Manage Alerts
Collapse Summary General Information
Company Eisai Co. Ltd.
DescriptionLiposomal formulation of E7389
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today